Cancel

You are now leaving information for the Philippines and entering the Takeda global section of our website. 
Please be aware that the content on the global site may differ from the country-specific content. 

Click 'Continue' to proceed to the global website, or 'Cancel' to remain on the current country site.

Continue

You are leaving the Takeda Philippines website

Learn more about Takeda in the Philippines

Since 1968, our subsidiary in the Philippines has been committed to improving patient access to treatment, guided by our values and sustainability.

Takeda Healthcare Philippines, Inc.

Divider Section Redesign

Takeda has been helping patients in the Philippines since 1968, when Takeda Pharmaceuticals Philippines Inc. was first founded. Since 2014, Takeda is represented in the Philippines by Takeda Healthcare Philippines Inc. which is the wholly owned subsidiary of Takeda Pharmaceutical Company Limited and aims to broaden patient access to treatment across the country through sustainable access programs and by strengthening the healthcare system guided by our commitment to Patients, our People and the Planet.


**Manila, Philippines** - Biopharmaceutical leader Takeda Healthcare Philippines, Inc. has proudly been Certified™ by Great Place To Work® for the third consecutive year. This prestigious award was based on substantial feedback from current employees, who confirmed a strong sense of belonging within the company.

The GPTW® survey results show that 97%\<sup>1\</sup> employees at Takeda Healthcare Philippines, Inc. report a positive experience and say it’s a great place to work, compared to 53% of employees at a typical global company.

“What amazes me about Takeda is its culture. It is a company that lives and breathes its values of Integrity, Honesty, Fairness, and Perseverance,” shared Takeda's CME Manager, Hazel Canlas. “These are not mere words posted on the walls but values that its employees live by. To me, more importantly, our leaders are very good examples of management that walks the talk.”

Headed by reputable and exceptional leaders, Access to Medicines (ATM) Lead, Sheryll Anne Corpuz disclosed that Takeda’s “tight-knit team feels like a family, fostering a supportive environment that truly feels like home.” Sharing the same sentiments with other employees, Corpuz is deeply grateful to be part of “a team that thrives in a balanced and healthy environment, promoting a strong sense of community and meaningful collaboration.”

In addition, 100% of employees from Takeda Healthcare Philippines, Inc. said that when you join the company, you are made to feel welcome. They also expressed that they perceive the company as approachable, easy to communicate with, and genuinely responsive to suggestions and ideas.

Takeda also recently ranked 6th in the small business category of the 2024 Philippines Best Workplaces List, reaffirming its commitment to providing a supportive and rewarding work environment for its employees.

Takeda is committed to fostering a diverse and inclusive workplace, exemplified by initiatives such as the Multi-Generation Workshop and the Sexual Orientation, Gender Identity, and Expression (SOGIE) Program. To support these initiatives, Takeda has implemented a wellness program that focuses on physical health, mental well-being, and work-life balance. This program includes fitness challenges, mental health workshops, coffee talks, weekly prayer sessions, and exercise activities to ensure that team members thrive both personally and professionally.

Additionally, the company established a wellness room, offering a dedicated space for relaxation, mindfulness activities, and stress relief. This initiative encourages employees to take short breaks, enhancing productivity and focus while reinforcing the company's commitment to fostering a positive work culture and retaining talent.

“We are honored and proud to be recognized as a Great Place To Work-Certified™ company for the third time,” said Loreann Villanueva, Country Manager of Takeda Healthcare Philippines Inc. “This achievement reflects our unwavering commitment to fostering a diverse and inclusive workforce, where every employee feels valued and respected. At Takeda, we celebrate our differences and promote the well-being of our team, ensuring a workplace that is free from any form of mistreatment, coercion, or discrimination. We are grateful for our employees’ dedication and hard work, who tirelessly contribute to a cause larger than themselves.”

Takeda also offers various initiatives to help employees balance their personal and professional needs, such as a hybrid work arrangement, no-meeting Fridays, flexible hours, study leave, and other benefits that promote work-life balance or integration. New activities based on employee suggestions, including painting classes and dance sessions, have also been introduced.

The company has executive coaching programs to help leaders enhance their leadership skills and provide personalized guidance tailored to their specific needs and goals. Through coaching, executives gain a deeper understanding of their strengths, weaknesses, and blind spots, leading to improved self-awareness and emotional intelligence. Coaches provide accountability and support, helping executives stay focused on their goals and navigate complex professional situations. Overall, executive coaching programs offer a range of benefits that contribute to the professional growth and success of executives and their organizations.

Moreover, Takeda aims to build on its success by sustaining and enhancing its workplace culture through continuous engagement initiatives. The company plans to actively gather employee feedback and leverage benchmarking to identify areas for improvement. By fostering an environment where employees feel heard and valued, Takeda is committed to creating a supportive and dynamic workplace that promotes growth, innovation, and well-being. This vision underscores their dedication to maintaining a thriving organizational culture that benefits both employees and the company as a whole.

According to a Great Place To Work Research,  job seekers are 4.5 times more likely to find a great boss at a Certified great workplace. Additionally, employees at Certified workplaces are 93% more likely to look forward to coming to work and are twice as likely to be paid fairly, earn a fair share of the company’s profits, and have a fair chance at promotion.

To learn more about Takeda Healthcare Philippines, Inc. and its initiatives, please visit takeda.com.

## About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R\&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.
Takeda Healthcare Philippines, Inc. (THPI) is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Founded in 2014, THPI aims to broaden patient access to treatment across the country through sustainable access programs enabling affordable and integrated access solutions for disease areas such as oncology, gastroenterology, rare diseases & vaccines and by strengthening the healthcare system guided by our commitment to Patients, our People and the Planet.
For more information, visit <https://www.takeda.com>.

## About Great Place to Work Certification™

Great Place To Work® Certification™ is the most definitive “employer-of-choice” recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place To Work-Certified.

### About Great Place To Work®

As the global authority on workplace culture, Great Place To Work® brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Their proprietary platform and For All™ Model helps companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified™ or receiving recognition on a coveted Best Workplaces™ List.
Learn more at [greatplacetowork.com](https://www.greatplacetowork.com/) and follow Great Place To Work on [LinkedIn](https://www.linkedin.com/company/28924/), [Twitter](https://twitter.com/gptw_us), [Facebook ](https://www.facebook.com/GreatPlacetoWork)and [Instagram](https://www.instagram.com/gptw_us).

## Media Contacts

### Takeda Healthcare Philippines, Inc.

Praveena Muniandi: <pra.muniandi@takeda.com>

### COMCO Southeast Asia

Ferdinand Bondoy: <ferdinand.bondoy@comcosea.com>

Joyce Yu: <joyce.yu@comcosea.com>

Clarissa Botecario: <clarissa.botecario@comcosea.com>

## References

*   [Takeda Healthcare Philippines, Inc. GPTW® Results](https://greatplacetowork.com.ph/companies/takeda-healthcare-philippines-inc/)



A Great Place To Work Certified™ for the Third Consecutive Year

Philippines Earns 3rd Great Place To Work Certification™

*   **Takeda Healthcare Philippines, Inc is listed in the 2023 Best Workplaces in Asia™**

*   **Takeda Healthcare Philippines is thrilled to be on the list for the first time**

*   **Best Workplaces in Asia award honors workplaces in Asia that provide exceptional work environments for their employees**

**Manila, Philippines, September 16, 2023** - Takeda Healthcare Philippines, Inc. (“Takeda”), a leading pharmaceutical company committed to promoting better health for people and a better future for the world, has been listed by the Great Place To Work®, the global authority on workplace culture, on the 2023 Best Workplaces in Asia™ List.

The 2023 Best Workplaces in Asia award honors workplaces in Asia that provide exceptional work environments for their employees, based on employee experience surveys that assess company culture and values. This prestigious recognition recognizes companies that prioritize employee well-being, foster a positive and inclusive workplace culture, and demonstrate outstanding practices in areas such as leadership, career development, and work-life balance.

“We are absolutely thrilled and proud to be listed as one of the Best Workplaces 2023 in Asia. This recognition underscores our unwavering commitment to nurturing a culture of trust, empowerment, and inspiration for our people to use their unique voices and talents to positively impact people’s lives every day – including their own,” said Loreann Villanueva, Country Manager of Takeda Philippines. “Creating a remarkable experience for our people is the first step in providing transformative healthcare solutions and contributing significantly to our society. By offering a diverse and inclusive work environment, job flexibility, and rewarding development opportunities, we make this possible. Our people are the heart of our success.”

Great Place to Work® encourages companies to continuously invest in their employees' growth and satisfaction, high-trust environment and ultimately contributing to the overall development of the respective industries. A Great Workplace is about the trust employees have with their leaders, the pride they have in their jobs and the happiness they experience with their colleagues, which has become increasingly important in today's competitive job market. Organizations on the list were selected from those that had participated in the Great Place to Work® renowned employee survey process.

Employees at Takeda Philippines are free to express their ideas, suggestions, and recommendations because the company is dedicated to maintaining a work environment that prioritizes creativity, collaboration, and diversity while fostering a respectable, honest, inclusive and speak up culture. This will help the business determine how to make long-lasting improvements. There are numerous opportunities for employees to openly discuss issues with their leaders, such as Coffee Talks and "Thank God It's Friday" sessions.

In addition, in the Philippines employees receive quarterly care packages from the company to make them feel valued. Fridays are also designated as "no meetings day," allowing employees to finish up any unfinished business, reorganize for the coming week, and start winding down for the weekend a little earlier. Not to mention, there are programs for leadership development, on-the-job training, and employee assistance initiatives that aim to help employees in need or develop their skills.  By doing this, Takeda Philippines gives its employees the tools they need to succeed and make a real difference in their work and ultimately the lives of others.

"Well-being is the cornerstone of our People-First culture. Our mission of ‘Better Health for People, Brighter Future for the World’ is only possible when we take care of our own people. Being listed among the Best Workplaces in Asia is a remarkable achievement for us. I am so proud of our team, so inspired by our people and so motivated by their energy,” added Villanueva.

As Takeda Healthcare Philippines celebrates this remarkable achievement, the company looks forward to building on its success and continuing to serve as an example of excellence in workplace culture not just across Asia but also around the globe.

The Best Workplaces in Asia List is published here: <https://www.greatplacetowork.com/asia-2023>

## About the 2023 Best Workplaces in Asia List

Great Place To Work selected the 2023 Best Workplaces in Asia List by analyzing companies’ workplace programs and surveying 2.1 million employees across multiple countries in Asia and the Middle East. The responses represent the experience of 5.9 million employees across the region.

To be considered, companies must first be identified as outstanding in their local region by appearing on one or more of our Best Workplaces™ Lists in Bahrain, Greater China (including China, Hong Kong, and Taiwan), India, Indonesia, Japan, Kuwait, Oman, Philippines, Qatar, Saudi Arabia, Singapore, South Korea, Sri Lanka, UAE, or Vietnam during 2022 or early 2023.

Companies rank in three size categories: small and medium (10–499 employees); large (500+ employees); and multinational. Multinational organizations are also assessed on their efforts to create great workplaces across multiple countries in the region. They must appear on at least two national lists in Asia and the Middle east and have at least 1,000 employees worldwide with at least 40% (or at least 5,000) of those employees located outside the headquarters country.

## About Great Place To Work

Great Place To Work is the global authority on workplace culture. Since 1992, it has surveyed more than 100 million employees around the world and used those deep insights to define what makes a great workplace: trust. Great Place To Work helps organizations quantify their culture and produce better business results by creating a high-trust work experience for all employees. Their unparalleled benchmark data is used to recognize Great Place To Work Certified™ companies and the Best Workplaces in more than 60 countries, including the World’s Best™ lists published annually in Fortune.

To learn more, visit greatplacetowork.com and read “A Great Place to Work For All.” Join the community on LinkedIn, Twitter, and Instagram.

## About Takeda

Takeda Pharmaceutical Company Limited ([TSE: 4502/NYSE: TAK](https://www.takeda.com/investors/)) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

## About Takeda Philippines

Takeda Healthcare Philippines, Inc. (THPI) is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Founded in 1968, THPI aims to broaden patient access to treatment across the country through sustainable access programs enabling affordable and integrated access solutions for disease areas such as oncology, gastroenterology, rare diseases & vaccines and by strengthening the healthcare system guided by our commitment to Patients, our People and the Planet.

For more information, visit [https://www.takeda.com](https://www.takeda.com/).

### Media Contacts:

**Takeda Philippines**

Arabella Benedito - [arabella.benito@takeda.com](mailto:arabella.benito@takeda.com)

**COMCO Southeast Asia**

Ferdinand Bondoy - [ferdinand.bondoy@comcosea.com](mailto:ferdinand.bondoy@comcosea.com)

Joyce Yu - [joyce.yu@comcosea.com](mailto:joyce.yu@comcosea.com)


Recognized for our exceptional workplace culture and employee well-being. Learn more about this prestigious achievement.

Takeda Healthcare Philippines Honored Among Asia’s Best Workplaces in 2023, Cited For Its Exceptional Workplace Culture

Takeda Healthcare Philippines Inc. (“Takeda Philippines”) recently partnered with Cancer Warriors Foundation Inc., a patient support organization for families of children with childhood cancer, strengthening calls for wider access to cancer care in rural and peri-urban communities in the country.

Through this partnership, Takeda will support the group’s initiatives and efforts in localizing the National Integrated Cancer Control Act (NICCA) by establishing Interlocal Health Zones, which are systemized zones made up of different local health facilities, dedicated to cancer care.

NICAA was signed into law in 2019, with the aim to ensure improved access, better quality care, and in the process, increased survivorship of cancer patients. The act also seeks to reduce the financial burden experienced by cancer patients and their families.

## The challenge continues

Cancer continues to be one of the leading causes of mortality in the Philippines<sup>1</sup> . With the rising number of cancer cases, access to care continues to be a challenge for several Filipinos, particularly for those residing in rural and peri-urban communities. Access to cancer information, services, support providers, and even clinical trials have been very limited. Given this, patients in these areas often present with advanced or late-stage cancers, and a significant number may go undiagnosed and unseen by medical practitioners.

To improve cancer care, increase curability, and create healthier communities, it is crucial to establish alliances across stakeholders and sectors. These collaborations will be instrumental in addressing the current gaps in cancer care delivery.

“NICCA not only focuses on basic integrated care, but also holistic care. Care should go beyond just the medical aspect, but also to the psychosocial aspect as well, including patients who survive cancer. Hence, it is crucial to form alliances with LGUs and other sectors to underline the importance of NICCA’s integrated and holistic approach to cancer care,” shared Carmen “Menchie” Auste, Chief Executive Officer of Cancer Warriors Foundation Inc.

## A uniting voice for localizing NICAA

Takeda has been a longstanding advocate of broadening access to medicines and supporting the Philippine government in strengthening the healthcare system. Through partnerships with non-profit organizations, patient groups, and key entities, Takeda engages in disease-awareness campaigns, policy advocacy, and advocacy network building, among other initiatives.

“Takeda looks forward to collaborating with Cancer Warriors Foundation in ensuring that NICCA becomes fully realized, which will help provide access to healthcare for cancer patients, their carers, and the general public, beginning with the establishment of Interlocal Health Zones,” Takeda Philippines Country Manager Loreann Villanueva shared.

The Cancer Warriors Foundation Inc., a non-profit organization dedicated to uniting parents against pediatric cancer, has long sustained calls for making cancer care accessible especially to patients and their families who take care and look after them.

“We hope that this partnership will zero-in on the implementation of the interlocal health zone, which will be a model of a how a primary health care system can be strengthened all the way up to the district level, essentially localizing the goal of NICAA to improve nationwide cancer healthcare,” Carmen “Menchie” Auste added. The first Interlocal Health Zone will be in CALABARZON Region, which the group sees as one of the priority regions for cancer care.

Takeda Healthcare Philippines is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, a global R\&D-driven biopharmaceutical company.

## About Takeda

Takeda Pharmaceutical Company Limited ([TSE: 4502/NYSE: TAK](https://www.takeda.com/investors/)) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

## About Takeda Philippines

Takeda Healthcare Philippines, Inc. (THPI) is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Founded in 1968, THPI aims to broaden patient access to treatment across the country through sustainable access programs enabling affordable and integrated access solutions for disease areas such as oncology, gastroenterology, rare diseases & vaccines and by strengthening the healthcare system guided by our commitment to Patients, our People and the Planet.

For more information, visit [https://www.takeda.com](https://www.takeda.com/).

### Media Contacts:

**Takeda Philippines**

Arabella Benedito - [arabella.benito@takeda.com](mailto:arabella.benito@takeda.com)

**COMCO Southeast Asia**

Ferdinand Bondoy - [ferdinand.bondoy@comcosea.com](mailto:ferdinand.bondoy@comcosea.com)

Joyce Yu - [joyce.yu@comcosea.com](mailto:joyce.yu@comcosea.com)

## Important Notice 

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. 

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. 

## Forward-Looking Statements 

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, 

“hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: <https://www.takeda.com/investors/sec-filings/> or at [www.sec.gov](http://www.sec.gov). Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results. 

## Medical information 

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. 

### References

1.  Philippine Statistics Authority, 2022. [https://psa.gov.ph/sites/default/files/attachments/crd/pressrelease/Press%20Release_3.pdf](https://psa.gov.ph/)


Partnering together to improve cancer care access in rural communities. Learn about the initiative to localize the National Integrated Cancer Control Act.

Takeda and Cancer Warriors Foundation unite for better cancer care access

Takeda Philippines Healthcare, Inc. (“Takeda”), a leading pharmaceutical company committed to create better health for people and a brighter future for the world, has been recognized with two prestigious awards at the Asia Responsible Enterprise Awards (AREA) ceremony held in Cambodia.

The first award was given to Takeda's Access To Medicines: Patient Assistance Program (AtM Program) in the Health Promotion category. Rooted in the vision of broadening access to life-changing medicines and vaccines in underserved communities, the AtM Program utilizes an integrated and sustainable approach that mobilizes the collective efforts of all involved stakeholders.

Focusing on diseases with the highest unmet need such as cancer and rare diseases, Takeda strives to bring its innovative and high-quality medicines to patients in the Philippines who have limited access to healthcare services. Through this program, the company has successfully provided financial assistance to over 600 patients nationwide, ensuring they receive crucial treatments regardless of their capacity to pay.

The AtM Program involves multi-stakeholder collaboration to address the pain points in the patient’s journey in the areas of disease awareness, accurate diagnosis, and appropriate treatment, support, and care. Based on Takeda’s insights on Filipino patients, it takes them about 5 to 10 visits to different doctors before they are properly diagnosed. Thus, the “Spot Lymphoma, Stop Lymphoma” campaign was launched together with 5 major medical societies and 2 non-government organizations to educate patients. Takeda in partnership with Philippine Cancer Society (PCS) provided CD30 screening through 24 hospitals majority of which are located outside of the capital of Metro Manila so patients would have access to CD30 screening.

Aside from screening, a series of workshops with Philippine Pathologists in partnership with medical societies were done to increase the skills and confidence of pathologists in utilizing immunohistochemistry and ensure early and proper diagnosis. The cornerstone of Takeda’s access program in the country is the Patient Assistance Program (PAP). This unique and innovative affordability-based program enabled more than 600 patients regardless of their socio-economic class to access their treatment with Takeda’s target therapy at a price that is based on the patient’s financial capacity to pay.

Takeda also partnered with an NGO to provide a series of training to oncology nurses to enrich their capability in educating patients. They also provided a grant to the Cancer Care Registry and Research Philippines Foundation (CARE PH) to expand its cancer registry and research.
Finally, as a culmination of Takeda’s holistic initiatives in 2022, the Access to Medicines (ATM) Summit gathered 137 multi-sectoral stakeholders from 42 organizations for a 2-day meeting, and discussed how each can support healthcare strengthening in the Philippines. Takeda’s framework is to build sustainable capacity at every stage from diagnosis to ongoing patient support. To date, more than 1,700 pathologists, 6,997 oncology and 5,683 endoscopy nurses, 4 medical societies, and 7 NGOs and patient organizations have partnered with Takeda in these endeavors.

The second award recognized Takeda for its unwavering dedication to employee well-being and engagement in the Investment in People category. These programs aim to foster a healthy and collaborative working environment, enabling employees to thrive personally and professionally.

Takeda's employee well-being and engagement programs encompass diverse wellness initiatives and engagement activities that encourage a robust and motivated workforce. From the Partnerships for Growth (PFG) mentoring program, Lunch and Learn sessions, to career development and energy management workshops, Takeda invests in its employees' growth and development. These engagement efforts cultivate open communication, collaborative relationships, and contribute to the company's talent development and retention strategies, resulting in sustained high engagement levels with an average of 92% in the last two years of the company’s annual engagement survey.

Takeda's dedication to its employees has also led to the prestigious Great Place to Work® certification for two consecutive years, as well as one of 2023 Philippines Best Workplaces. The company remains steadfast in ensuring its programs cater to the needs of its workforce, empowering them to flourish and reach their full potential.

"We are honored to receive these recognitions as it cements Takeda’s enduring commitment to serve communities as well as our employees," Loreann Villanueva, Country Manager of Takeda Healthcare Philippines Inc. said. "These awards inspire us to push the boundaries further, making a lasting difference to the Filipino community through an empowered and highly dedicated workforce."

AREA recognizes and honors deserving Asian businesses for championing sustainable and responsible business practices in the following categories: Green Leadership, Social Empowerment, Health Promotion, Investment in People, Corporate Governance, Circular Economy Leadership, Corporate Sustainability Reporting and Responsible Business Leadership.

## About Takeda

Takeda Pharmaceutical Company Limited ([TSE: 4502/NYSE: TAK](https://www.takeda.com/investors/)) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

## About Takeda Philippines

Takeda Healthcare Philippines, Inc. (THPI) is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Founded in 1968, THPI aims to broaden patient access to treatment across the country through sustainable access programs enabling affordable and integrated access solutions for disease areas such as oncology, gastroenterology, rare diseases & vaccines and by strengthening the healthcare system guided by our commitment to Patients, our People and the Planet.

For more information, visit [https://www.takeda.com](https://www.takeda.com/).

### Media Contacts:

**Takeda Philippines**

Arabella Benedito - [arabella.benito@takeda.com](mailto:arabella.benito@takeda.com)

**COMCO Southeast Asia**

Ferdinand Bondoy - [ferdinand.bondoy@comcosea.com](mailto:ferdinand.bondoy@comcosea.com)

Joyce Yu - [joyce.yu@comcosea.com](mailto:joyce.yu@comcosea.com)

### Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

### Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”,

“hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

### Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

Honored for our Access to Medicines program and commitment to employee well-being. Learn more about our sustainable and responsible business practices.

Takeda Healthcare Philippines receives double recognition at the Asia Responsible Enterprise Awards

## Takeda Philippines Press Releases



As our workforce continues to grow, we have the opportunity to transform lives by providing innovative treatments. We take pride in our numerous awards, which recognize our unwavering commitment to expanding patient access to cutting-edge treatments.

Equally important to us is fostering a workplace environment that promotes innovation, diversity, and collaboration. Join us in making a difference and be part of a company that is dedicated to improving lives!


## Careers



## Contact Us



Takeda Philippines

Links to sites outside of takeda.com are provided as a resource to the audiences. Please note that Takeda is not responsible or liable for any third-party website and the website may not be appropriate for all audiences. 

To stay on the current website, select “Cancel”


Philippines

Takeda Philippines Press Releases

Philippines Earns 3rd Great Place To Work Certification™

Takeda Healthcare Philippines Honored Among Asia’s Best Workplaces in 2023, Cited For Its Exceptional Workplace Culture

Takeda and Cancer Warriors Foundation unite for better cancer care access

Takeda Healthcare Philippines receives double recognition at the Asia Responsible Enterprise Awards

Careers

Our recent Awards

Great Place to Work

Best Workplaces in the Philippines

Best Workplaces in Asia

Asia Responsible Enterprise Awards - Area

Asia Corporate Excellence and Sustainability Awards - ACES

Contact Us